Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback